Archive for 2013

  • 松下修三, 大類 諭, Post F, Winston J, Hendry B, Gazzard B, Molina J, Liu HC, Piontkowsky D, Cheng AK, Rhee MS, Szwarcberg J. EVG/COBI/FTC/TDF 第III 相臨床試験における腎機能に関連する安全性の評価(投与96 週時点)-アジア人についての層別集計結果を含む-. 第27回日本エイズ学会学術集会・総会. 2013年11月20日-22日, 熊本.

  • 桑田岳夫. シンポジウム6-中和抗体と抗CCR5 阻害薬(Env). 第27回日本エイズ学会学術集会・総会.  2013年11月20日-22日, 熊本.

  • Ramirez K, Kuwata T, Maruta Y, Tanaka K, Alam M, Kawanami Y, Enomoto I, Tamamura H, Yoshimura K, Matsushita S. Combination of anti-V3 antibodies as a possible strategy for controllingtransmitted/founder virus. 第27回日本エイズ学会学術集会・総会. 2013年11月20日-22日, 熊本.

  • 丸田泰広, 桑田岳夫, 田中和樹, Ramirez K, Alam M, 江上由華, 中原悠介, 諏訪喜昭, 森岡弘志, 松下修三. 抗V3 抗体の小型化によるCD4 結合後のHIV-1 中和活性の増進. 第27回日本エイズ学会学術集会・総会. 2013年11月20日-22日, 熊本.

  • Alam M, Kuwata T, Ramirez K, Enomoto I, Maruta Y, Tanaka K, Rahman K, Egami Y, Kawanami Y, Murayama H, Shimura K, Matsuoka M, Matsushita S. Enfuvirtide resistant mutation N43Dis associated with the enhancedneutralization by 10E8, a broadlyneutralizing antibody against gp41 MPER. 第27回日本エイズ学会学術集会・総会. 2013年11月20日-22日, 熊本.

  • 田中和樹, 桑田岳夫, 丸田泰広, Ramirez K, 松下修三. gp120のCD4-induced epitope に結合する中和抗体の小型化とその特性の検討. 第27回日本エイズ学会学術集会・総会. 2013年11月20日-22日, 熊本.

  • Alam M, Kuwata T, Ramirez K, Enomoto I, Maruta Y, Tanaka K, Rahman K, Egami Y, Kawanami Y, Murayama H, Shimura K, Matsuoka M, Matsushita S. Effects of Enfuvirtide resistant mutations on the sensitivity to neutralizing antibodies. 14th Kumamoto AIDS Seminar. 29-31 October 2013, Kumamoto.

  • Maruta Y, Kuwata T, Tanaka K, Nakahara Y, Ramirez K, Alam M, Egami Y, Suwa Y, Morioka H, Matsushita S. Post-attachment neutralization as a mechanism of efficient activities of scFv from anti-V3 monoclonal antibody. 14th Kumamoto AIDS Seminar. 29-31 October 2013, Kumamoto.

  • Tanaka K, Kuwata T, Maruta Y, Ramirez K, Kawanami Y, Enomoto I, Matsushita S. Miniaturization of antibodies against CD4-induced epitope on gp120. 14th Kumamoto AIDS Seminar. 29-31 October 2013, Kumamoto.

  • Ramirez K, Kuwata T, Maruta Y, Tanaka K, Alam M, Rahman K, Egami Y, Kawanami Y, Enomoto I, Tamamura H, Yoshimura K, Matsushita S. Can antibodies contribute to controlling infection with transmitted/founder virus? 14th Kumamoto AIDS Seminar.  29-31 October 2013, Kumamoto.

  • Kuwata T, Takaki K, Yoshimura K, Enomoto I, Wu F, Ourmanov I, Hirsch VM, Yokoyama M, Sato H, Matsushita S. Identification of the Env region responsible for the resistance to B404, a potent neutralizing antibody against SIV. 14th Kumamoto AIDS Seminar. 29-31 October 2013, Kumamoto.

  • Otsuki, H., Hishiki, T., Miura, T., Hashimoto, C., Narumi, T., Tamamura, H., Yoshimura, K., Matsushita, S., and Igarashi, T. Generation of a replication-competent simian-human immunodeficiency virus, the neutralization sensitivity of which can be enhanced in the presence of a small-molecule CD4 mimic. J. Gen. Virol. 94: 2710-2716, 2013.

  • Hashimoto, C., Narumi, T., Otsuki, H., Hirota, Y., Arai, H., Yoshimura, K., Harada, S., Ohashi, N., Nomura, W., Miura, T., Igarashi, T., Matsushita, S. and Tamamura, H. A CD4 mimic as an HIV entry inhibitor: Pharmacokinetics. Bioorg. Med. Chem. 21: 7884-7889 , 2013.

  • Ramirez K, Kuwata T, Maruta Y, Tanaka K, Alam M, Rahman K, Kawanami Y, Enomoto I, Tamamura H, Yoshimura K, Matsushita S. Improving the brodality and potency of neutralizing anti-HIV-1 antibodies with a CD4 mimetic compound. AIDS Vaccine 2013. 7-10 October 2013. Barcelona, Spain.

  • Kuwata T, Takaki K, Yoshimura K, Enomoto I, Wu F, Ourmanov I, Hirsch VM, Yokoyama M, Sato H, Matsushita S. Analysis of Env regions important for binding and resistance to B404, a potent neutralizing antibody against SIV. AIDS Vaccine 2013. 7-10 October 2013. Barcelona, Spain.

  • The Mind Exchange Working Group (Antinori A, Arendt G, Grant I, Matsushita S, et al.) Assessment, Diagnosis, and Treatment of HIV-Associated Neurocognitive Disorder: A Consensus Report of the Mind Exchange Program. Clin Infect Dis. 56(7):1004 -1017, 2013

     

  • Harada S, Yoshimura K, Yamaguchi A, Yusa K, Matsushita S. Impact of antiretroviral pressure on selection of primary HIV-1 envelope sequences in vitro.  J. Gen. Virol. 94:933-943, 2013.

     

  • Kuwata T, Takaki K, Yoshimura K, Enomoto I, Wu F, Ourmanov KI, Hirsch VM, Yokoyama M, Sato H, Matsushita S. Conformational Epitope Consisting of the V3 and V4 Loops as a Target for Potent and Broad Neutralization of Simian Immunodeficiency Viruses.  J. Virol. 87:5424-5346, 2013.

     

  • Narumi T, Arai H, Yoshimura K, Harada S, Hirota Y, Ohashi N, Hashimoto C, Nomura W, Matsushita S, Tamamura H.: CD4 mimics as HIV entry inhibitors: lead optimization studies of the aromatic substituents.  Bioorganic & Medicinal Chemistry. 21:2518-2526, 2013 .

     

  • Kuwata T, Takaki K, Enomoto I, Kazuhisa Y, and Matsushita S. Increased infectivity in human cells and resistance to antibody-mediated neutralization by truncation of the SIV gp41 cytoplasmic tail.   Frontiers in Microbiology/Virology. 4:1-7, 2013.

     

  • Nishijima T, Takano M, Ishisaka M, Komatsu H, Gatanaga H, Kikuchi Y, Endo T, Horiba M, Kaneda S, Uchiumi H, Koibuchi T, Naito T, Yoshida M, Tachikawa N, Ueda M, Yokomaku Y, Fujii T, Higasa, S., Takada, K., Yamamoto, M, Matsushita S, Tateyama M, Tanabe Y, Mitsuya H, Oka S, on behalf of the Epzicom-Truvada study team: Abacavir/Lamivudine versus Tenofovir/Emtricitabine with Atazanavir/Ritonavir for Treatment-naive Japanese Patients with HIV-1 Infection: A Randomized Multicenter Trial.  Internal Medicine. 52: 735-744, 2013.

  • Matsushita S., Yoshimura K., Maeda T., Murakami T., KD-1002 Principal Investigators and The Protocol Team of Quintiles.  Passive transfer of neutralizing monoclonal antibody KD-247 reduces plasma viral load in patientschronically infected with HIV-1: a phase-1b clinical study of a humanized monoclonal antibody KD-247 (KD-1002). 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) , 30 June –3 July 2013 , Kuala Lumpur.

     

  • Matsushita S., Yoshimura K., Maeda T., Murakami T., KD-1002 Principal Investigators and The Protocol Team of Quintiles. Passive transfer of neutralizing monoclonal antibody KD-247 reduces plasma viral load in patientschronically infected with HIV-1: a phase-1b clinical study of a humanized monoclonal antibody KD-247 (KD-1002).

  • Matsushita S.  Passive transfer of neutralizing monoclonal antibody KD-247 reduces plasma viral load in patients chronically infected with HIV-1:A Phase-1b clinical study of a humanized monoclonal antibody KD-247 (KD-1002).  IAS Towards an HIV Cure Symposium. 29-30 June 2013 , Kuala Lumpur.

     

  • 平成26年度大学院医学教育部(修士・博士)入試説明会が開催されます。

    当研究室(エイズ学II分野)もポスター展示や、オープンラボも開催予定です!!

    • 会場:熊本大学・医学総合研究棟3階 講習室
    • 日時:平成25年5月11日(土)11:30〜17:00まで

    大学院入試に関しての詳細はこちら→医学教育部ホームページ